Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.51 and last traded at $17.49, with a volume of 3403236 shares trading hands. The stock had previously closed at $17.04.
Silverback Therapeutics Stock Performance
The company has a market cap of $507.70 million, a price-to-earnings ratio of -5.82 and a beta of 0.60. The firm’s 50-day moving average price is $14.26 and its 200 day moving average price is $11.54.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- How to Invest in the Best Canadian Stocks
- Rocket Lab is the Right Stock for the Right Time
- 3 Tickers Leading a Meme Stock Revival
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
